$CANLF - Glaucoma Therapy Entering into Phase 1 Cl
Post# of 228
Posted On: 06/24/2014 7:41:21 AM
$CANLF - Glaucoma Therapy Entering into Phase 1 Clinical Trials
Vancouver, BC - June 24, 2014 Cannabis Technologies Inc. (CSE: CAN, OTCQB: CANLF) is pleased to announce its first therapy, CT1-085, which is a topical formulation containing a proprietary compound of cannabinoids and non-cannabis based active ingredients for the treatment of Glaucoma.
Cannabis Technologies Inc. has identified our lead composition (CTI 085) through 12 months of discovery and preclinical studies that showed efficacy in lowering intraocular pressure (IOP) in animal models. Cannabinoids have IOP lowering effects, thus, they have therapeutic potential in the treatment of glaucoma. Dr Hossain, Chief Scientific Officer states, "Our objective was to develop a safer; cannabis based topical anti-glaucoma formulation without systemic side effects. We are pleased to have successfully completed our pre-clinical trials which are in the process of the clinical development of the formulation".
Craig Schneider, President & CEO states, "The successful discovery & development of CTI-085 demonstrates to the market that our proprietary Cannabinoid Drug Design Platform (CDP) can successfully identify treatments within our proposed target areas. We are looking forward to the continuation of expanding our product pipeline through the utilization of our Platform Technology."
Ophthalmic Market
Ophthalmic Drugs Market (Dry eye, Anti-glaucoma, Anti-allergy/ inflammatory/ infective, Retinal Drugs) - the global ophthalmic drugs market was valued at USD 16 billion in 2012 and is expected to grow at a CAGR of 5.2% from 2013 to 2018, to reach an estimated value of USD 21.6 billion in 2018. Globally, the ophthalmic drugs market is witnessing significant growth due to increasing prevalence of eye disorders such as diabetic retinopathy and macular degeneration. As a result, this market is expected to grow at a CAGR of about 5.2% during 2013 - 2018. Some of the key driving factors for the ophthalmic drugs market are rising prevalence of global aging population, increasing government initiatives towards healthcare infrastructure in developing countries (such as India and China),technological changes in drug delivery technique, and increasing prevalence of lifestyle associated diseases.
About Cannabis Technologies ("CTI"
CTI is a biopharmaceutical drug discovery and development company uniquely focused on the pharmacology and therapeutic potential of cannabinoids.
CTI is utilizing its proprietary "Cannabinoid Drug Design Platform" to identify new bioactive compounds within the marijuana plant that interact with certain genes responsible for specific diseases.
Our extensive research and intellectual properties will initially be focused on the development of several new cannabinoid based treatments for Ophthalmic, Cancer & Angiogenesis, and Inflammation, Pain.
ON BEHALF OF THE BOARD
"Craig Schneider"
President and CEO
For further information, please visit the company's website at www.cannabis-tech.com
Cannabis Technologies Inc.
Craig Schneider
President and Chief Executive Officer
Tel: 604.669.7207
info@cannabis-tech.com
www.cannabistech.com
Vancouver, BC - June 24, 2014 Cannabis Technologies Inc. (CSE: CAN, OTCQB: CANLF) is pleased to announce its first therapy, CT1-085, which is a topical formulation containing a proprietary compound of cannabinoids and non-cannabis based active ingredients for the treatment of Glaucoma.
Cannabis Technologies Inc. has identified our lead composition (CTI 085) through 12 months of discovery and preclinical studies that showed efficacy in lowering intraocular pressure (IOP) in animal models. Cannabinoids have IOP lowering effects, thus, they have therapeutic potential in the treatment of glaucoma. Dr Hossain, Chief Scientific Officer states, "Our objective was to develop a safer; cannabis based topical anti-glaucoma formulation without systemic side effects. We are pleased to have successfully completed our pre-clinical trials which are in the process of the clinical development of the formulation".
Craig Schneider, President & CEO states, "The successful discovery & development of CTI-085 demonstrates to the market that our proprietary Cannabinoid Drug Design Platform (CDP) can successfully identify treatments within our proposed target areas. We are looking forward to the continuation of expanding our product pipeline through the utilization of our Platform Technology."
Ophthalmic Market
Ophthalmic Drugs Market (Dry eye, Anti-glaucoma, Anti-allergy/ inflammatory/ infective, Retinal Drugs) - the global ophthalmic drugs market was valued at USD 16 billion in 2012 and is expected to grow at a CAGR of 5.2% from 2013 to 2018, to reach an estimated value of USD 21.6 billion in 2018. Globally, the ophthalmic drugs market is witnessing significant growth due to increasing prevalence of eye disorders such as diabetic retinopathy and macular degeneration. As a result, this market is expected to grow at a CAGR of about 5.2% during 2013 - 2018. Some of the key driving factors for the ophthalmic drugs market are rising prevalence of global aging population, increasing government initiatives towards healthcare infrastructure in developing countries (such as India and China),technological changes in drug delivery technique, and increasing prevalence of lifestyle associated diseases.
About Cannabis Technologies ("CTI"
CTI is a biopharmaceutical drug discovery and development company uniquely focused on the pharmacology and therapeutic potential of cannabinoids.
CTI is utilizing its proprietary "Cannabinoid Drug Design Platform" to identify new bioactive compounds within the marijuana plant that interact with certain genes responsible for specific diseases.
Our extensive research and intellectual properties will initially be focused on the development of several new cannabinoid based treatments for Ophthalmic, Cancer & Angiogenesis, and Inflammation, Pain.
ON BEHALF OF THE BOARD
"Craig Schneider"
President and CEO
For further information, please visit the company's website at www.cannabis-tech.com
Cannabis Technologies Inc.
Craig Schneider
President and Chief Executive Officer
Tel: 604.669.7207
info@cannabis-tech.com
www.cannabistech.com
(0)
(0)InMed Pharmaceuticals, Inc. (INM) Stock Research Links
Scroll down for more posts ▼